Ocular Microbiology and Immunology Group
Back to OMIG Main Page

2012 Agenda and Abstracts | < Previous | Next >

2012 OMIG Abstract 21

Efficacy of Voriconazole and Amphotericin B as Additives in
Optisol-GS Against Candida Species
N. Layer¹, V. Cevallos², B.H. Jeng^1,2
1Dept. of Ophthalmology and ²Francis I. Proctor Foundation, University of California San Francisco, San Francisco, CA

Purpose: Optisol-GS is the most commonly used corneal storage medium in the United States; however, it currently does not include an antifungal additive. This study evaluates the efficacy of adding either voriconazole or amphotericin B to Optisol-GS in reducing Candida contamination of the media.

Methods: Vials of Optisol-GS were supplemented with either voriconazole at 1x, 10x, 25x, or 50x minimum inhibitory concentration (MIC) or amphotericin B at 0.25x, 0.5x, 1x, or 10x MIC. Unsupplemented control groups were also used. Isolates of C. albicans and C. glabrata were each added to a set of Optisol-GS vials. The vials were refrigerated at 4 degrees C. On days 2 and 7, 1 mL of the solution was removed and sampled for viable colony counts immediately after removal from refrigeration and after warming to room temperature for 2 hours.

Results: No benefit was observed with voriconazole supplementation to Optisol-GS against C. albicans or C. glabrata, with growth of both organisms in all voriconazole-supplemented vials. Viable counts of C. albicans were effectively reduced with supplementation of amphotericin B at all concentrations evaluated. Viable counts of C. glabrata were effectively reduced with amphotericin B supplementation at 1x and 10x MIC.

Conclusions: The addition of amphotericin B, but not voriconazole, to Optisol-GS may significantly improve activity against Candida contamination.

Disclosure: S     Richard Lindstrom/Eye Bank Association of America Research Fund, That Man May See

2012 Agenda and Abstracts | < Previous | Next >